Work

Orexin receptor antagonists for major depressive disorder: perspectives from a systematic review and meta-analysis

Year: 2026

Type: review

Abstract: A recent report by Dr. Hashimoto in Molecular Psychiatry highlighted that, because the orexin system in mesolimbic pathways modulates reward and motivation, it is important to monitor mood changes in individuals with insomnia treated with orexin receptor antagonists (QXR-ANTs) [ 1 ]. Orexin receptors comprise two subtypes: OX1R and OX2R.

Source: Molecular Psychiatry

DOI: 10.1038/s41380-026-03599-z

Authors: Taro Kishi, Kenji Sakuma, Masakazu Hatano, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata

Institution: Fujita Health University

Language: English

Topic: Treatment of Major Depression

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,490